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Abstract
Dyneins are major components of microtubules. Dynein assembly
is modulated by a heterogeneous group of dynein axonemal assem-
bly factors (DNAAFs). The present study analyzes dynein axonemal
assembly factor 1 (DNAAF1) and leucine-rich repeat-containing
protein 50 (LRRC50), the corresponding encoded protein, in lower
motor neurons in spinal cord of sALS postmortem samples and
hSOD1-G93A transgenic mice compared with controls. DNAAF1
mRNA is significantly reduced in the anterior horn in sALS, and
LRRC50 immunoreactivity is significantly reduced in C-boutons of
the remaining motor neurons of the anterior horn, dorsal nucleus of
the vagus nerve, and hypoglossal nuclei at terminal stages of ALS.
LRRC50 immunoreactivity has a perinuclear distribution in motor
neurons in sALS thus suggesting a disorder of transport. The number
of LRRC50-/S1R-immunoreactive structures is also significantly de-
creased in hSOD1-G93A transgenic mice at the age of 90 days
(preclinical stages), and the number of motor neurons with LRRC50-
immunoreactive structures is significantly reduced in animals aged
150 days (clinical stages). These observations suggest cholinergic de-
nervation of motor neurons as a pathogenic factor in motor neuron dis-
ease. LRRC50 protein levels were not detected in human CSF.
Key Words: Amyotrophic lateral sclerosis, Biomarkers, Dynein ax-
onemal assembly factor 1, LRRC50, Motor-neurons, Spinal cord.
INTRODUCTION
Neuronal microtubules are intracellular structures that
facilitate a myriad of neuronal functions, including activity-
dependent axonal transport (1), which is governed by the dy-
nein/kinesin system (2, 3). Anterograde transport, mediated by
kinesins, supplies distal axons with newly synthesized proteins
and lipids, including synaptic components required to main-
tain presynaptic activity, whereas retrograde transport, medi-
ated by dyneins, is required to maintain homeostasis by
removing aging proteins and organelles from the distal axon
for degradation and recycling of components (1, 3).
Dynein is a dimer composed of the motor-containing
heavy chain and the distal tail formed by intermediate chains,
light intermediate chains, and light chains. The motor domain
is in the C-terminus and is responsible for microtubule bind-
ing, inasmuch as the N-terminal tail domain is responsible for
dimerization, dynein interaction with other proteins (e.g.
dynactin), and cargo interaction (3–6).
Amyotrophic lateral sclerosis (ALS) is a multifactorial
disease characterized by the degeneration of motor neurons,
their axons, and neuromuscular synapses (7, 8). Microtubule
alterations, including abnormal kinesin/dynein and related
interactors, are critical factors in the pathogenesis of this dis-
ease (9–18). In addition, Golgi complex disruption results
from abnormal dynein/dynactin interactions (6). Since recent
transcriptomics observations have identified significant reduc-
tion in the expression of a cluster involving several axonemal
dynein transport components in the anterior horn of the spinal
cord (SC) in sporadic ALS (sALS) (19), the ensuing study ana-
lyzes dynein axonemal assembly factor 1 (DNAAF1) and
leucine-rich repeat-containing protein 50 (LRRC50), the cor-
responding encoded protein, in lower motor neurons in sALS
compared with controls. LRRC50 is a dynein up-stream effec-
tor that participates in the cytoplasmic preassembly of dynein
arms and is involved in the regulation of microtubule-based
cilia and actin-based brush border microvilli. Different
mutations in LRRC50 result in distinct clinical syndromes,
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including abnormal assembly of cilia in respiratory epithelia
producing primary ciliary dyskinesia, altered cardiac lateral-
ity, and polycystic kidney (20–22). The distribution and locali-
zation of LRRC50 in the nervous system is not known. The
present study has identified LRRC50 in C-boutons of motor
neurons of the SC and selected motor nuclei of the brain stem
in sALS, and decreased LRRC50 immunoreactivity in sALS




Paraffin-embedded postmortem fresh-frozen and 4%
formalin-fixed samples of the lumbar SC and medulla oblon-
gata were obtained from the Institute of Neuropathology
HUB-ICO-IDIBELL Biobank following the guidelines of the
Spanish legislation (Real Decreto de Biobancos 1716/2011)
and the approval of the local ethics committee of the Bellvitge
University Hospital-Institute of Biomedical Research IDI-
BELL. The postmortem interval between death and tissue
processing was from 2 to 17 hours. Transversal sections of the
SC were alternatively frozen at –80C or fixed by immersion
in 4% buffered formalin. Age-matched control cases had not
suffered from neurologic or psychiatric diseases and did not
have neuropathologic lesions. Genetic testing, using genomic
DNA isolated from blood or brain tissue, revealed no muta-
tions in the chromosome 9 open reading frame (C9orf72), su-
peroxide dismutase 1 (SOD1), TAR DNA binding protein
(TARDBP), or FUS RNA binding protein (FUS). Cases in the
present series used for biochemical studies (i.e. quantitative
reverse transcription PCR [RT-qPCR]) are summarized in the
Table. Cases used for immunohistochemical studies did not
correspond always with those of the biochemical series; this
group was composed of 16 sALS 10 age-matched controls as
described in the corresponding section. Variable numbers of
TDP-43-P-immunoreactive neuronal and oligodendroglial
inclusions and neuropil threads were found in the anterior
horn of the SC in every ALS case. Neuronal inclusions were
small, round intracytoplasmic deposits, large globular inclu-
sions and skein-like inclusions. Neuronal inclusions were pre-
sent in only20% of the remaining motor neurons in ALS.
Animal Model hSOD1-G93A
Transgenic mice expressing high copy numbers of the
mutated form of human SOD1 (hSOD1), B6SJL-Tg(SOD1*
G93A)1Gur/J (hSOD1-G93A) were obtained from The Jack-
son Laboratories (Bar Harbor, ME). The colony was main-
tained by breeding male hemizygous carriers with
nontransgenic B6SJL females. Offspring were identified by
PCR, and non-transgenic G93A littermates were used as wild-
type controls. In addition, unrelated WT mice were examined.
Animals were maintained under standard animal housing con-
ditions (static isolation caging, 3–4 animals per cage) in a
12-hour dark-light cycle with free access to food and water.
The first series of immunohistochemical studies was per-
formed on 5 hSOD1-G93A mice, 3 control littermates, and 3
WT aged 150 days. The second series of histochemical studies
was carried out on the SCs of 5 animals per stage: 90 days
(preclinical), 120 (early clinical), and 150 (late clinical). Gen-
otyped mice were dissected for immunohistochemical studies.
All the procedures were carried out after the approval of the
Animal Ethics Committee of the University of LLeida.
RNA Extraction and RT-qPCR
RNA from dissected human frozen anterior horn of the
lumbar SC of 14 sALS (mean age 61 years; 6 men and
8 women) and 13 age-matched controls (mean age 59 years;
8 men and 5 women) was extracted following the instructions
of the supplier (RNeasy Mini Kit, Qiagen, Hilden, Germany).
RNA integrity and 28S/18S ratios were determined with the
Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA)
to assess RNA quality, and the RNA concentration was evalu-
ated using a NanoDrop Spectrophotometer (Thermo Fisher
Scientific, Waltham, MA). Complementary DNA (cDNA)
preparation used the High-Capacity cDNA Reverse Transcrip-
tion kit (Applied Biosystems, Foster City, CA) following the
protocol provided by the supplier. Parallel reactions for each
RNA sample were run in the absence of MultiScribe Reverse
TABLE. Summary of Cases Used for Biochemical Study
RIN Value
Case Age Gender Diagnosis PM Delay Initial
Symptoms
SC
1 59 M Control 12 h 05 min – 6.4
2 43 M Control 05 h 55 min – 6.6
3 47 M Control 04 h 55 min – 5.6
4 64 F Control 11 h 20 min – 6.2
5 46 M Control 15 h 00 min – 5.9
6 56 M Control 07 h 10 min – 6.1
7 71 F Control 08 h 30 min – 5.9
8 64 F Control 05 h 00 min – 7.0
9 79 F Control 06 h 25 min – 6.7
10 75 M Control 07 h 30 min – 5.0
11 55 M Control 09 h 45 min – 5.3
12 76 M Control 06 h 30 min – 6.6
13 51 F Control 04 h 00 min – 6.3
14 56 M sALS 10 h 50 min N/A 7.1
15 70 M sALS 03 h 00 min Respiratory 7.3
16 77 M sALS 04 h 30 min N/A 7.4
17 56 F sALS 03 h 45 min N/A 8.2
18 59 M sALS 03 h 15 min N/A 7.5
19 63 F sALS 13 h 50 min Bulbar 6.8
20 59 F sALS 14 h 15 min N/A 6.4
21 64 M sALS 16 h 30 min N/A 6.3
22 57 F sALS 04 h 00 min Bulbar 6.2
23 75 F sALS 04 h 05 min Bulbar 6.8
24 79 F sALS 02 h 10 min N/A 7.0
25 57 F sALS 10 h 00 min Bulbar 6.5
26 46 M sALS 07 h 00 min Spinal 7.0
27 69 F sALS 17 h 00 min Spinal 6.4
Abbreviations: sALS, sporadic amyotrophic lateral sclerosis cases; M, male;
F, female; PM delay, postmortem delay (hours, minutes); N/A, not available; RIN,
RNA integrity number.
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Transcriptase to assess the lack of contamination of genomic
DNA. TaqMan RT-qPCR assays for DNAAF1 (Hs00698
399_m1) were performed as detailed elsewhere (19).
Hypoxanthine-guanine phosphoribosyltransferase (HPRT1)
was used as internal control for normalization of SC samples.
The double-delta cycle threshold (DDCT) method was utilized
to determine the fold change values. The obtained data were
analyzed with the t-test.
Immunohistochemistry
Dewaxed 4-lm-thick sections of the SC and medulla
oblongata in human cases and SC in mice were processed for
immunohistochemistry. The human series included 16 sALS
(mean age 57 years; 6 men and 8 women) and 10 age-matched
controls (mean age 62 years; 6 men and 4 women). Immuno-
histochemistry in murine SCs was performed in 5 3 trans-
genic mice (5 animals at the ages of 90, 120, and 150 days)
and 3 2 controls (3 control littermates and 3 WT aged
150 days). The sections were boiled in citrate buffer
(20 minutes) to retrieve protein antigenicity. Endogenous per-
oxidases were blocked by incubation in 10% methanol-1%
H2O2 solution (15 minutes) followed by 3% normal horse se-
rum solution. Then the sections were incubated at 4C over-
night with one of the primary antibodies: LRRC50 (1/200,
polyclonal rabbit, Abcam, Cambridge, UK); vesicular acetyl-
choline transporter: VAChT (1/100, polyclonal guinea pig,
Synaptic Systems, Goettingen, Germany); and sigma 1 recep-
tor: S1R (1/100, monoclonal mouse, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). Following incubation with the primary
antibody, the sections were incubated with EnVisionþ system
peroxidase (Dako, Agilent Technologies) for 30 minutes at
room temperature. The peroxidase reaction was visualized
with diaminobenzidine and H2O2. Control of the immunos-
taining included omission of the primary antibody; no signal
was obtained following incubation with only the secondary
antibodies. No positive controls were used.
Double-Labeling Immunofluorescence and
Confocal Microscopy
Dewaxed 4-lm-thick sections of human and mouse con-
trol SCs were stained with a saturated solution of Sudan black
B (Merck, Glostrup, Denmark) for 15 minutes to block the
autofluorescence of lipofuscin granules present in cell bodies,
and then rinsed in 70% ethanol and washed in distilled water.
The sections of human cases were incubated at 4C overnight
with double combinations (double-labeling) of LRRC50
(1/200, polyclonal rabbit, Abcam, Cambridge, UK) and
VAChT (1/100, polyclonal guinea pig, Synaptic Systems) or
S1R (1/100, monoclonal mouse, Santa Cruz Biotechnology)
or synaptophysin (monoclonal mouse antibody used at 1/500,
Leica Biosystems, Wetzlar, Germany) or TDP43-P Ser409/
Se410 (1:200, MABN14 rat, Millipore, Burlington, MA).
Other sections were triple labeled with LRRC50, VAChT, and
S1R. The sections of mice were processed for double-labeling
immunofluorescence with antiLRRC50 and antiS1R antibod-
ies. After washing, the sections were incubated with the respec-
tive fluorescence secondary antibodies Alexa555, Alexa488,
and/or Alexa657 (1:400, Molecular Probes, Eugene, OR)
against the corresponding host species. Nuclei were stained
with DRAQ5 (dilution 1:2000, BioStatus, Loughborough,
UK). After washing, the sections were mounted in Immuno-
Fluore mounting medium (ICN Biomedicals, Irvine, CA),
sealed, and dried overnight. Sections were examined with a
Leica TCS-SL confocal microscope. Control of the immunos-
taining included omission of the primary antibody; no signal
was obtained following incubation with only the secondary
antibodies.
Quantification and Statistical Analysis
Quantification of LRRC50 expression in human histo-
logical sections was made directly from the ocular of the mi-
croscope at a magnification of 200 by counting the number
of motor-neurons containing LRRC50-positive boutons in
(i) the whole anterior horn of the lumbar SC, (ii) motor nu-
cleus of the vagus nerve, and (iii) hypoglossal nucleus (HN) in
3 different sections separated 100mm for every region in every
sALS and control case. A similar approach was used to quan-
tify motor-neurons with VAChT- and S1R-positive structures.
Quantitative studies in mice were carried out only in the ven-
tral horn of the SC following the same protocol. Quantification
was made by one person blinded to the clinical status. The nor-
mality of distribution of counted cell number was analyzed
with the Kolmogorov-Smirnov test. The unpaired t-test was
performed to compare each group when values followed a nor-
mal distribution. Statistical analysis and graphic design were
performed with GraphPad Prism version 5.01 (La Jolla, CA).
Results were analyzed with the Student t-test. Outliers were
detected using the GraphPad software QuickCalcs (p< 0.05).
The data were expressed as mean 6 SEM and significance lev-
els were set at *p< 0.05, **p< 0.01, and ***p< 0.001.
ELISA in CSF
Samples were obtained from sALS patients and controls
as detailed elsewhere (23). CSF (1.5 6 0.5 mL) was collected
in polypropylene tubes as part of the clinical routine investiga-
tion. CSF was centrifuged at 3000 rpm for 15 minutes at room
temperature. Supernatant was collected and aliquoted in vol-
umes of 250 lL and stored at –80C until use. All samples
were analyzed after one freeze/thaw cycle. Quantification of
LRRC50 was performed using the Human Dynein assembly
factor 1, axonemal, LRRC50 ELISA Kit (Catalogue N
MBS9317767, MyBiosource, San Diego, CA) following the
manufacturer’s instructions.
RESULTS
In agreement with a previous study (19), DNAAF1
mRNA expression levels in the anterior horn of the SC were
significantly reduced in sALS compared with controls
(p¼ 0.019; Fig. 1A).
LRRC-50 immunoreactivity in the human control SC
and brainstem was restricted to immunoreactive boutons in
motor neurons, and walls in the blood vessels. Such boutons
were elongated, oval-shaped, 1–5 lm in length, and mainly lo-
calized at the periphery of the cytoplasm near the plasma
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membrane of the cell body and proximal dendrites (Fig. 1B,
C). The number of LRRC50-immunoreactive boutons per neu-
ron was as high as twenty-five in a single paraffin section.
However, the number of LRRC50-immunoreactive boutons
was markedly reduced in the remaining motor neurons in the
anterior horn of the SC in sALS cases (p¼ 1.10 1018;
Fig. 1D–F). Similar LRRC50-immunoreactive boutons were
found in contact with the cytoplasm and proximal dendrites of
motor neurons in the dorsal motor nucleus of the vagus nerve
and the HN in control cases, but their number was smaller in
comparison with anterior horn motor neurons. A similar re-
duction in the number of LRRC50-immunoreactive boutons
was found in the remaining motor neurons in the dorsal motor
nucleus of the vagus nerve (p¼ 1.2 107) and in the HN
(p¼ 4.3 108) in sALS (Fig. 1G–I). Curiously, LRRC50 in
several motor neurons in sALS had a perinuclear distribution
instead of its presence in boutons (Fig. 1I).
In contrast to the motor nuclei of the hypoglossal nuclei
and vagus nerves, LRRC50-positive boutons were absent in
the oculomotor nuclei of the brainstem in normal (control)
brains (data not shown).
LRRC50 structures were similar in morphology to C-
boutons on motor neurons of the spinal horn, as revealed by
vesicular acetylcholine transporter (VAChT) and sigma 1 re-
ceptor (S1R) immunohistochemistry (Fig. 2). Moreover,
VAChT- and S1R-positive motor neuron boutons were largely
decreased in sALS cases (p¼ 8.75 106 and p¼ 1.15
1012, respectively; Fig. 2E, H).
FIGURE 1. DNAAF1 and LRRC50 expression in human control and sALS lower motor neurons. (A) Reduced DNAAF1 mRNA
expression in the anterior horn of the lumbar spinal cord in sALS compared with age-matched controls. (B, C) LRRC50
immunoreactivity in anterior horn motor neurons in controls identifies oval-shaped structures (boutons) at the periphery of the
cytoplasm and proximal dendrites. (D) The percentage of motor neurons with LRRC50-immunoreactive dots is significantly
decreased in the anterior horn of the spinal cord (SC) in sALS when compared with controls. (E, F) This decrease is due to the
almost total absence of LRRC50-positive boutons in the remaining sALS motor neurons. (G) Similar reduction is found in the
hypoglossal nucleus (HN) and motor nucleus of the vagus nerve (DNV) in sALS when compared with controls. (H, I)
Representative images of the motor nucleus of the vagus nerve in control and sALS showing marked reduction, almost absence
of LRRC50-immunoreactive boutons. Note perinuclear LRRC50 immunoreactivity in some motor neurons in sALS (arrows) but
not in controls. LRRC50 immunoreactivity is also present in capillaries (ca). Paraffin sections slightly counterstained with
hematoxylin; scale bar¼25 mm. Unpaired t-test, *p<0.05, ***p<0.001.
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Double- and triple-labeling immunofluorescence to
LRRC50 and S1R, VAChT, and synaptophysin in controls
showed that LRRC50-immunoreactive boutons colocalized or
were in close contact with VAChT or with S1R and
synaptophysin-immunoreactive C-boutons (Fig. 3), thus sup-
porting the idea that LRRC50 was a component of C-boutons.
Double-labeling immunofluorescence and confocal micros-
copy to LRRC50 and TDP-43-P showed that loss of C-boutons
was found equally in neurons with and without TDP-43-P-
imunoreactive inclusions. This was not unexpected as
TDP-43-P inclusions were observed in a minority of
remaining motor neurons in ALS whereas loss of LRRC50
boutons was generalized in the anterior horn of the SC in ALS
(data not shown).
Motor neurons of the SC in control mice (SOD1 litter-
mates and WT mice) showed similar oval or round LRRC50-
immunoreactive structures in the cytoplasm (Fig. 4).
LRRC50-positive structures were in close proximity or colo-
calized with S1R as revealed by double-labeling immunofluo-
rescence and confocal microscopy (Fig. 4). No differences
were seen between control littermates and WT mice at the age
of 150 days. However, LRRC50 positivity was significantly
decreased in motor neurons in hSOD1-G93A transgenic mice
aged 150 days (p¼ 0.001; Fig. 4).
To learn whether loss of LRRC50 immunoreactivity
was an early or a late event in the progression of motor
neuron degeneration, hSOD1-G93A transgenic mice at pre-
clinical and early clinical stages, 90 and 120 days old, re-
spectively, were examined. As shown in Figure 5, the
number of positive structures per neuron was already de-
creased at the age of 90 days (preclinical stage) in hSOD1-
G93A transgenic mice compared with controls (p¼ 0.03).
The reduction was still noted at the age of 120 days although
it was not significant (p¼ 0.14).
Finally, to test whether LRRC50 in the CSF might serve
as a complementary biomarker in sALS, LRRC50 levels were
measured using a commercial quantitative sandwich ELISA
kit. The detection range was from 3.12 ng/mL to 100 ng/mL.
Levels of LRRC50 were not detectable in the CSF of controls
and sALS cases.
FIGURE 2. Sigma 1 receptor (S1R) and vesicular acetylcholine transporter (VAChT) immunoreactivity in motor neurons of the
spinal cord in control and sALS. (A, B) S1R-immunoreactive C-boutons are found at the surface of the cytoplasm and proximal
dendrites in controls. (C, D) Immunoreactive C-boutons practically disappear in the remaining motor neurons in sALS. (E) The
graph illustrates that the percentage of neurons with S1R-positive C-boutons is significantly decreased in sALS compared with
controls. (F, G) Representative images of VAChT-immunoreactive C-boutons in control and ALS; remaining ALS motor neurons
are almost devoid of VAChT C-boutons. (H) The graph illustrates the significant reduction of the percentage of neurons with
VAChT-positive C-boutons in sALS compared with controls. Paraffin sections slightly counterstained with hematoxylin; scale
bar¼25 mm. Unpaired t-test, ***p<0.001.
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DISCUSSION
Dynein processing and localization varies in
different cell types and clusters in distinct subcellular organ-
elles (24–27). In the central nervous system, dyneins are
largely localized at the axon terminals (27). Dynein assembly
is modulated by a heterogeneous group of DNAAFs that act,
in most instances, in combination with particular chaperones
to promote cytoplasmic pre-assembly of dyneins (28–33).
Mutations in certain DNAAFs such as NADYX1C1, ZYYND10,
C11orf70 (encoding CFAP300: cilia and flagella associated
protein 300), and PIH1D3result in abnormal dynein assembly
(30, 34–40). Likewise, mutations in DNAAF1 result in abnor-
mal assembly of cilia in respiratory epithelia, infertility, al-
tered cardiac laterality, and polycystic kidney (20–22).
The present study identifies the presence of LRRC50-
immunoreactive boutons at the surface of motor neurons of the
FIGURE 3. Double-labeling (upper panel) and triple-labeling (lower panel) immunofluorescence and confocal microscopy to
LRRC50 and sigma 1 receptor (S1R), vesicular acetylcholine transporter (VAChT) or synaptophysin (SYN) in normal motor
neurons of the human lumbar spinal cord. Upper panel: LRRC50-immunoreactive boutons (red) colocalize S1R-immunoreactive
C-boutons (green), VAChT-positive C-boutons (green), and large synaptophysin terminals (green) at the periphery of the
cytoplasm and proximal dendrites (arrows) of motor neurons (asterisks). Merge shows, in addition, nuclei stained with DRAQ5
(blue). Lower panel: LRRC50 (green) colocalizes VAChT (red) and S1R (blue) in C-boutons (long arrows: merge: white); some
structures colocalize VAChT and S1R but not VAChT (thick arrow). Paraffin sections; scale bar¼30 mm except upper row in which
bar¼50 mm.
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SC and motor nuclei of the brain stem in humans and mice,
which are identified as C-boutons on the basis of single immu-
nohistochemistry, and double- and triple-labeling immunofluo-
rescence and confocal microscopy. C-boutons are pre-synaptic
terminals of cholinergic interneurons localized in the SC and in
most of the motor nuclei of the cranial nerves excepting the ocu-
lomotor nuclei of the brainstem (41–47). They contain VAChT
and synaptic vesicle markers, and are in contact with postsynap-
tic components including M2 muscarinic receptors and S1R;
neuregulin 1-ErB retrograded signaling is also differentially
compartmentalized in C-type boutons (43, 46–49). Cholinergic
interneurons modulate motor neuron activity through C-boutons
(43–45, 50). On the basis of the present findings, LRRC50 may
be considered a component of C-boutons involved in dynein as-
sembly and retrograde axonal transport.
In agreement with our previous gene transcription obser-
vations, DNAAF1 mRNA expression is reduced in the SC an-
terior horn in sALS cases. Reduced DNAAF1 mRNA
expression can be the result of mere motor neuron demise.
However, LRRC50 immunoreactivity is drastically reduced at
the surface of the remaining spinal and bulbar motor neurons,
in parallel with reduced numbers of C-boutons, in sALS.
FIGURE 4. LRRC50-immunoreactive boutons in motor neurons of the spinal cord in mice. (A, B) LRRC-50 immunoreactivity is
found in cytoplasmic structures in control mice. (C) Double-labeling immunofluorescence and confocal microscopy depicts close
proximity and partial colocalization of LRRC50 (green) and S1R (red) immunoreactivity. (D) LRRC50 immunoreactivity is almost
depleted in motor neurons in hSOD1-G93A transgenic mice aged 150 days (clinical stage). (E) Quantification of motor-neurons
with LRRC50-positive structures is significantly reduced in transgenic mice when compared with wild type littermates. Unpaired
t-test: ***p<0.001. Paraffin sections; scale bars: A, B, D, bar¼25 mm; C¼15 mm.







/jnen/advance-article-abstract/doi/10.1093/jnen/nlz019/5426209 by Bukkyo U
niversity Library user on 03 April 2019
FIGURE 5. LRRC50 (red) and S1R (green) immunoreactivity in motor-neurons of the ventral horn of the spinal cord in control
and hSOD1-G93A transgenic mice aged 90 (A, B) and 120 (C, D) days. LRRC50 and S1R immunoreactivity is decreased in
transgenic animals when compared with controls (A–D), although some LRRC50- and S1R-positive structures are still present in
neurons in transgenic mice. Asterisks indicate the localization of the cytoplasm of motor neurons. (E) Quantitative studies show a
significant decrease in the number of LRRC50- and S1R-immunoreactive structures in transgenic mice aged 90 days (preclinical
stage) and a trend at the age of 120 days when compared with control littermates. Unpaired t-test: *p<0.05. Paraffin sections;
scale bar¼25 mm.
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Therefore, LRRC50 reduction is not the mere reflection of
motor neuron demise but a reduction in the number of
LRRC50-immunoreactive boutons in the remaining motor
neurons in sALS.
This decline occurs independently of the aberrant for-
mation of TDP-43-immunoreactive inclusions in certain mo-
tor neurons in classical sALS (7, 8). This decline neither
corelates with the appearance of dynein-dynactin-
immunoreactive deposits in motor neurons, which are also not
related with skein-like inclusions, in the SC in sALS (51).
However, LRRC50 reduction in C-boutons is accompanied by
perinuclear LRRC50 immunoreactivity in some remaining
motor neurons thus suggesting some kind of alteration in the
transport of this protein.
Loss of cholinergic synapses in the SC motor-neurons in
sALS was reported many years ago (52). That pioneering ob-
servation was not studied further in humans but was partially
refuted in SOD1 transgenic mice (53, 54). This is due in part
to the different markers used to detect C-boutons in SOD1
transgenic mice. A significant increase in the number of
NRG1-positive boutons was observed at the beginning of the
symptomatic stage which was followed by a marked decrease
at end stages of the disease. A similar pattern occurred for
VAChT boutons, but some motor-neurons depleted of
VAChT-immunoreactive boutons showed high numbers of
NRG1-positive dots (46). Our present observations show a
marked reduction in LRRC50-immunoreactive boutons in mo-
tor neurons of the ventral horn in hSOD1-G93A transgenic
mice aged 150 days which is accompanied by a parallel de-
crease in, but not the absence of, S1R-immunoreactive bou-
tons. The presence of the remaining S1R seems to be
protective of motor neurons, as the knocking-out of S1R in
hSOD1-G93A transgenic mice exacerbates motor neuron dis-
ease progression in these animals (55). Early pre-symptomatic
alterations in C-boutons has been reported in SOD1(G93A) tg
mice (56). Interestingly, viral-mediated delivery of type III-
NRG1 to the SC restores the number of C-boutons and extends
the survival time of SOD1-ALS mice (57).
Our combined study in human sALS not linked to
SOD1 mutations and in transgenic mice bearing high copy
numbers of the mutated form of human SOD1 show common
responses regarding C-boutons in motor neurons. The number
of LRRC50-immunoreactive structures is decreased in motor
neurons in both paradigms. To learn whether observed altera-
tions in ALS are early or late events, transgenic mice at pre-
clinical, early clinical and late clinical stages were examined.
A decrease in LRRC50 immunoreactivity occurs at preclinical
stages in hSOD1-G93A transgenic mice, suggesting that
LRRC50 alteration is an early event in the course of the dis-
ease. A trend to decrease is observed at the age of 120; lack of
significance can be due to the relative low number of animals
examined or to a transient attempt to compensation. However,
a significant decrease is manifested at the age of 150 days.
The pattern of C-bouton response in sALS and Tg mice
differs from that seen after nerve peripheral nerve axotomy in
mice. Reduced expression of VAChT and NRG1
immunoreactivity together with a reduction in size of C-bou-
tons starting at 24 hours is followed by practical recovery by
30 days postlesion (47, 58). Therefore, the changes observed
here in motor neuron disease are hardly due to peripheral
axotomy.
Whether LRRC50 in motor neurons is essential for the
maintenance of C-boutons cannot be addressed by neuropath-
ological approach. Yet this is an important point for under-
standing the role of this protein in motor neuron maintenance
and neurodegeneration.
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